Advertisement
Advertisement
VNDA
Vanda Pharmaceuticals Inc.
5.04
USDSponsored
-0.17
-3.26%
Sep 23, 15:59 UTC -4
Closed
After-Market
5.10
+0.06
+1.19%
VNDA Earnings Reports
Positive Surprise Ratio
VNDA beat 29 of 41 last estimates.
71%
Next Report
Date of Next Report
Oct 27, 2026
Estimate for Q3 26 (Revenue/ EPS)
$70.69M
/-$0.68
Implied change from Q2 26 (Revenue/ EPS)
+39.89%
/-34.62%
Implied change from Q3 25 (Revenue/ EPS)
+25.65%
/+78.95%
Vanda Pharmaceuticals Inc. earnings per share and revenue
On Aug 05, 2026, VNDA reported earnings of -1.04 USD per share (EPS) for Q2 26, missing the estimate of -0.59 USD, resulting in a -73.54% surprise. Revenue reached 50.53 million, compared to an expected 63.16 million, with a -20.00% difference. The market reacted with a +0.49% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.68 USD, with revenue projected to reach 70.69 million USD, implying an decrease of -34.62% EPS, and increase of 39.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Vanda Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Vanda Pharmaceuticals Inc. reported EPS of -$1.04, missing estimates by -73.54%, and revenue of $50.53M, -20% below expectations.
How did the market react to Vanda Pharmaceuticals Inc.'s Q2 2026 earnings?
The stock price moved up 0.49%, changed from $5.09 before the earnings release to $5.12 the day after.
When is Vanda Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Oct 27, 2026.
What are the forecasts for Vanda Pharmaceuticals Inc.'s next earnings report?
Based on 5
analysts, Vanda Pharmaceuticals Inc. is expected to report EPS of -$0.68 and revenue of $70.69M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.